Anthropic PBC has introduced Claude Science, a new artificial intelligence platform aimed at streamlining scientific research workflows by automating routine tasks that have long consumed researchers' time and resources. The system became available on June 30 to paid users in beta form, representing the company's latest effort to position AI as an indispensable tool across professional sectors. By consolidating access to more than 60 scientific databases and enabling researchers to issue commands in everyday language rather than navigating complex query systems, Claude Science aims to reshape how scientists approach data analysis, hypothesis testing, and experimental design.
The platform is built to handle multistep research processes across biology and chemistry, including protein structure prediction, which has historically required significant computational investment and specialized expertise. Rather than forcing scientists to switch between disparate tools and databases, Claude Science presents an integrated interface that can interpret natural language questions and retrieve relevant information from numerous sources simultaneously. This consolidation addresses a persistent inefficiency in research environments, where investigators frequently must cross-reference multiple databases, each with its own syntax and limitations, to gather comprehensive information for a single study or analysis.
AnthropⱭic's announcement came during a San Francisco event where Chief Executive Officer Dario Amodei outlined the company's ambitions in drug discovery and life sciences. The gathering included Vas Narasimhan, Chief Executive of Novartis AG and a board member at Anthropic, alongside Chris Boerner, CEO of Bristol-Myers Squibb Co. The presence of major pharmaceutical leaders signalled serious corporate commitment to AI-driven research acceleration, a recognition that traditional drug development timelines increasingly burden healthcare innovation and patient access to treatments. Amodei expressed hope that within the coming year, Claude Science would demonstrate tangible progress in identifying new drug targets, moving beyond promotional language toward demonstrable clinical outcomes.
AnthropⱭic's expansion into life sciences extends beyond simply offering software tools. The company announced it has begun developing its own internal preclinical drug discovery programs, a strategic pivot that signals confidence in its AI capabilities and a willingness to stake commercial reputation on the technology's ability to generate medical breakthroughs. According to Eric Kauderer-Abrams, Anthropic's head of life sciences, the company intends to focus on therapeutic areas that major pharmaceutical and biotechnology corporations may deem less commercially attractive or sufficiently profitable to investigate, potentially addressing gaps in treatment options for rare diseases or neglected conditions.
The Claude Science announcement reflects broader competition between Anthropic and OpenAI to establish AI tools across high-value professional domains. Both companies have accelerated development of AI applications targeting finance, legal services, healthcare, and scientific research throughout the past year, seeking to justify substantial valuations and expand their customer bases beyond consumer applications. Anthropic, currently valued at US$965 billion (RM3.94 trillion), has indicated its intention to pursue an initial public offering potentially as early as autumn, suggesting it views near-term commercialization of these tools as critical to its financial strategy and public market positioning.
Recent Anthropic initiatives have generated significant market volatility and raised investor concerns about technological disruption. In February, the company introduced Claude Cowork, a tool automating legal work including contract review and the preparation of legal briefings. That announcement triggered a US$1 trillion (RM4.08 trillion) stock market selloff, reflecting broader anxiety about which professional services and career categories artificial intelligence may render unnecessary or marginal. Claude Science carries similar implications, as automation of research tasks could eventually reshape employment in scientific fields and alter the competitive dynamics of pharmaceutical research and development.
For Southeast Asian readers and institutions, Anthropic's expansion into life sciences research automation carries particular relevance. The region's emerging biotechnology sector and growing investment in medical research infrastructure could benefit significantly from access to such tools, particularly for smaller research institutions and nations with less established scientific computing ecosystems. Malaysian universities and research bodies increasingly focus on biomedical innovation, drug discovery, and tropical disease research; Claude Science could potentially accelerate progress in these areas while also raising questions about dependency on foreign AI infrastructure and intellectual property ownership of research outputs generated through the platform.
The technology underpinning Claude Science relies on existing Anthropic models, particularly Opus 4.8, released in May. A key feature distinguishes the system from less rigorous AI applications: Claude Science includes traceable documentation showing how the platform reached its conclusions, enabling scientists to verify accuracy and identify sources. This transparency mechanism addresses a critical vulnerability in applying AI to research, where unverified or hallucinated information could contaminate results and compromise scientific integrity. Similarly, images generated through the platform include methodological details about how they were produced, allowing peer reviewers and collaborators to assess reliability.
Narasimhan from Novartis, while endorsing AI's potential in drug discovery, emphasized the importance of establishing regulatory frameworks before crises force intervention. He stated that appropriate AI governance should be implemented proactively rather than reactively, warning that waiting for adverse events to catalyze regulatory action represents a failure of foresight. This stance reflects growing recognition among industry leaders that AI development without concurrent regulatory development risks catastrophic public health or safety incidents that could set back the entire field.
AnthropⱭic's recent experience with government restrictions on AI access demonstrates the regulatory complexities surrounding advanced technology. The company disabled access to its most advanced models, Fable 5 and Mythos 5, in response to Trump administration orders designed to prevent foreign nationals from accessing certain AI capabilities. Subsequently, on June 26, Anthropic obtained approval to restore partial access to Mythos 5 after addressing national security concerns raised by the administration. However, no announcement has clarified whether restrictions on Fable 5 will be similarly relaxed, indicating ongoing tensions between AI companies and government agencies regarding technology control, national security, and international competitiveness in artificial intelligence development.
